Izumino K, Iida H, Asaka M, Mizumura Y, Sasayama S
Nephron. 1986;43(1):56-61. doi: 10.1159/000183719.
The effect of the antiplatelet agents ticlopidine and dipyridamole on immune complex glomerulonephritis in rats was evaluated. Bovine serum albumin (BSA) nephritis was induced in rats with subcutaneous immunization and intravenous dosage of BSA. Ticlopidine and dipyridamole were administered for 4 weeks before and for 7 days after onset of proteinuria. It was shown that both ticlopidine and dipyridamole could reduce the development of proteinuria when administered before the onset of proteinuria. Ticlopidine also reduced the amount of urinary protein after onset of proteinuria, and may thus be more effective against urinary protein excretion. When the antiplatelet agents were administered before onset of glomerulonephritis, blood urea nitrogen and serum creatinine levels were significantly lower, and glomerular hypercellularity and mesangial widening were milder in animals treated with ticlopidine than in controls. Glomerular deposition of BSA was less intense in treated animals than in nontreated controls. Thus, ticlopidine as well as dipyridamole was found to inhibit the development of proteinuria and glomerular alteration. It is suggested that ticlopidine could be more effective than dipyridamole against the development of immune complex glomerulonephritis in rats.
评估了抗血小板药物噻氯匹定和双嘧达莫对大鼠免疫复合物性肾小球肾炎的影响。通过皮下免疫和静脉注射牛血清白蛋白（BSA）诱导大鼠患BSA肾炎。在蛋白尿发作前4周和发作后7天给予噻氯匹定和双嘧达莫。结果表明，在蛋白尿发作前给药，噻氯匹定和双嘧达莫均可减少蛋白尿的发展。噻氯匹定还可降低蛋白尿发作后的尿蛋白量，因此可能对尿蛋白排泄更有效。在肾小球肾炎发作前给予抗血小板药物时，噻氯匹定治疗的动物血尿素氮和血清肌酐水平显著较低，肾小球细胞增多和系膜增宽较对照组轻。治疗动物肾小球中BSA的沉积强度低于未治疗的对照组。因此，发现噻氯匹定和双嘧达莫均可抑制蛋白尿的发展和肾小球改变。提示噻氯匹定在对抗大鼠免疫复合物性肾小球肾炎的发展方面可能比双嘧达莫更有效。
